Publications by authors named "Priya Sriraman"

CC-90002 is an anti-CD47 antibody that inhibits CD47-SIRPα interaction and enables macrophage-mediated killing of tumor cells in hematological cancer cell lines. In this first clinical, phase 1, dose-escalation and -expansion study (CC-90002-AML-001; NCT02641002), we evaluated CC-90002 in patients with relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). CC-90002 was administered in escalating doses of 0.

View Article and Find Full Text PDF
Article Synopsis
  • β-Thalassemia is a genetic blood disorder that causes issues with hemoglobin production, leading to the need for regular blood transfusions and potential complications like iron overload.
  • Luspatercept is the first approved therapy in the U.S. that helps improve anemia in adult patients with β-thalassemia who rely on these transfusions, showing effective dosage and reduced transfusion needs.
  • Studies indicate that luspatercept has a favorable safety profile and its administration is based on body weight, making it a promising alternative therapy for managing β-thalassemia.
View Article and Find Full Text PDF
Article Synopsis
  • Luspatercept is a fusion protein that helps improve late-stage red blood cell development and has been studied in 260 patients with anemia from myelodysplastic syndromes.
  • The drug has predictable pharmacokinetics and its dosage varies from 0.125 to 1.75 mg/kg, with body weight being the main factor for determining the correct dose.
  • The findings indicate that higher serum levels of luspatercept improve the chances of patients achieving transfusion independence and experiencing fewer severe side effects, supporting a dose range of 1.0 to 1.75 mg/kg for effective long-term treatment.
View Article and Find Full Text PDF
Article Synopsis
  • The 2018 Workshop on Recent Issues in Bioanalysis was held in Philadelphia with over 900 attendees from various sectors, focusing on bioanalysis, biomarkers, and immunogenicity over five days.
  • The workshop aimed to facilitate discussions on current topics in bioanalysis, including small- and large-molecule assays utilizing LCMS and other methods, and resulted in comprehensive recommendations outlined in a White Paper.
  • The White Paper is divided into three parts, with Part 3 specifically addressing large molecule bioanalysis and related topics, while Parts 1 and 2 cover small molecules and hybrid approaches, respectively.
View Article and Find Full Text PDF

An antibody-drug conjugate (ADC) is a unique therapeutic modality composed of a highly potent drug molecule conjugated to a monoclonal antibody. As the number of ADCs in various stages of nonclinical and clinical development has been increasing, pharmaceutical companies have been exploring diverse approaches to understanding the disposition of ADCs. To identify the key absorption, distribution, metabolism, and excretion (ADME) issues worth examining when developing an ADC and to find optimal scientifically based approaches to evaluate ADC ADME, the International Consortium for Innovation and Quality in Pharmaceutical Development launched an ADC ADME working group in early 2014.

View Article and Find Full Text PDF

The L4 Global Harmonization Team on reagents and their stability focused on the management of critical reagents for pharmacokinetic, immunogenicity, and biomarker ligand binding assays. Regulatory guidance recognizes that reagents are important for ligand binding assays but do not address numerous aspects of critical reagent life cycle management. Reagents can be obtained from external vendors or developed internally, but regardless of their source, there are numerous considerations for their reliable long-term use.

View Article and Find Full Text PDF

The University of Wisconsin bioanalytical conference is presented each year by the Extension Services in Pharmacy, the professional development department within the School of Pharmacy. The purpose of this 3-day conference was to provide an educational forum to discuss issues and applications associated with the analysis of xenobiotics, metabolites, biologics and biomarkers in biological matrices. The conference was designed to include and encourage an open exchange of scientific and methodological applications for bioanalysis.

View Article and Find Full Text PDF

CD81 is an essential receptor for hepatitis C virus (HCV). K21 is a novel high affinity anti-CD81 antibody with potent broad spectrum anti-HCV activity in vitro. The pharmacokinetics (PK), pharmacodynamics and liver distribution of K21 were characterized in cynomolgus monkeys after intravenous (i.

View Article and Find Full Text PDF

We describe a development of a novel high-throughput phagocytosis assay based on a pH-sensitive cyanine dye, CypHer5E, which is maximally fluorescent in an acidic environment. This dye is ideally suited for the study of phagocytosis because of the acidic conditions generated in the intracellular phagocytic vesicles after particle uptake. Use of CypHer5E-labeled particles results in greatly reduced background from noninternalized particles and makes the assay more robust.

View Article and Find Full Text PDF

Expression of the plastid rRNA operon (rrn) during development is highly regulated at the level of transcription. The plastid rrn operon in most higher plants is transcribed by the plastid-encoded RNA polymerase (PEP), the multisubunit plastid RNA polymerase from PrrnP1, a sigma(70)-type promoter with conserved -10 and -35 core promoter elements. To identify functionally important sequences, the tobacco PrrnP1 was dissected in vivo and in vitro.

View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Notice

Message: fwrite(): Write of 34 bytes failed with errno=28 No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 272

Backtrace:

A PHP Error was encountered

Severity: Warning

Message: session_write_close(): Failed to write session data using user defined save handler. (session.save_path: /var/lib/php/sessions)

Filename: Unknown

Line Number: 0

Backtrace: